<DOC>
	<DOC>NCT01588405</DOC>
	<brief_summary>This multi-center, open-label study will assess the tolerability and safety of transitioning subjects with stable Pulmonary Arterial Hypertension (PAH) from continuous intravenous (IV) or subcutaneous (SC) Remodulin infusion to oral treprostinil (UT-15C sustained release (SR) tablets). This study will consist of an in-hospital transition phase, dose optimization/evaluation phase, and follow up phase.</brief_summary>
	<brief_title>RemodulinÂ® to Oral Treprostinil Transition</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Between 15 and 80 years of age, inclusive, weigh at least 40 kg and have a diagnosis of PAH Have stable disease as confirmed by recent right heart catheterization and a Baseline 6MWD of at least 250 meters Have been receiving Remodulin for at least 90 days and at a stable dose for at least 30 days prior to the Baseline visit; the dose of Remodulin must be between 2575 ng/kg/min, inclusive Must be also receiving an endothelin receptor antagonist (ERA) and/or a phosphodiesterase5 inhibitor (PDE5i) for at least 90 days and have been at a stable dose for at least 30 days prior to Baseline WHO functional class III and IV subjects will be excluded</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>UT-15C SR</keyword>
	<keyword>PAH</keyword>
</DOC>